EMA Refused: Zeftera (previously Zevtera) (ceftobiprole medocaril) — Janssen-Cilag International NV

View source ↗

Summary

The EMA refused approval for Zeftera (ceftobiprole medocaril) from Janssen-Cilag International NV for skin and soft tissue infections, with decision dated 16/09…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin Diseases
• Soft Tissue Infections

Drugs mentioned

• Zeftera (Zevtera) (ceftobiprole medocaril)

Snippet

Status: Refused. Therapeutic area: Skin Diseases, Infectious;Soft Tissue Infections. MAH: Janssen-Cilag International NV. Decision date: 16/09/2010